6-Fluoro-3-hydroxypyrazine-2-carboxamide
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
259793-96-9- Standard-SMILES
NC(=O)c1nc(F)c[nH]c1=O- InChIKey
ZCGNOVWYSGBHAU-UHFFFAOYSA-N- Summenformel
- C5H4FN3O2
- Durchschnittliche Molmasse
- 157,104 g/mol
- Monoisotopische Masse
- 157,02875459
Namen und Bezeichner
- Bevorzugter Name
- 6-Fluoro-3-hydroxypyrazine-2-carboxamide
- IUPAC
- 6-Fluoro-3-hydroxypyrazine-2-carboxamide
- Englischer Name
- Favipiravir
- Summenformel
- C5H4FN3O2
- Molmasse
- 157.1
Namen und Synonyme
6-Fluoro-3-hydroxypyrazine-2-carboxamideT-7056-fluoro-3,4-dihydro-3-oxo-PyrazinecarboxamideAviganFavipiravi6-fluoro-3,4-dihydro-3-oxo- (9CI)6-Fluoro-3-hydroxy-2-pyrazinecarboxamidePyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo- (9CI)Farapiwe3-Dithian
Datenbank-Bezeichner
- CAS
259793-96-9- PubChem CID
- 492405
- DTXSID
DTXSID60948878- ChEMBL
CHEMBL221722- ChEBI
CHEBI:134722- UNII
- EW5GL2X7E0
- EC Number
- 856-840-0
- Nikkaji
- J1.636.682J
Eigenschaften
Physikochemische Eigenschaften
- Schmelzpunkt
- 151 °C · >151°C (dec.)
- Dichte
- 1.78 · 1.78±0.1 g/cm3(Predicted)
- storage temp.
- 2 · under inert gas (nitrogen or Argon) at 2-8°C
- Löslichkeit
- Soluble in DMSO (30 mg/mL), water (12 mg/mL with warming)
- pka
- 8.77 · 8.77±0.60(Predicted)
- Aggregatzustand
- solid
- Farbe
- Off-white
- Stabilität
- 1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO or water may be stored at -20° for up to 3 months.
- InChI
- InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
- InChIKey
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N
- SMILES
- C1(C(N)=O)=NC(F)=CNC1=O
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- wgk
- WGK 3
- Speicherklasse
- 11 - Combustible Solids
- Hazard Classifications
- Muta. 2Repr. 2
Chemie und Industrie
Anwendungen
BeschreibungFavipiravir, 6-fluoro-3-hydroxypyrazine-2-carboxamide, is a new broad-spectrum antiviral drug targeting RNA-dependent RNA polymerase (RdRp) developed by Japan's Toyama Chemical Pharmaceutical Company. It was approved for marketing in Japan in March 2014 for the treatment of new and recurrent influenza. During the outbreak of the new coronavirus, the results of the Phase I clinical study of the drug published in March 2020 showed that the drug may have the effect of speeding up virus clearance to alleviate the progress of new coronavirus pneumonia.
HistoryFavipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.
VerwendenFavipiravir is used for the treatment of advanced Ebola virus infection in a small animal model. It suppressed the replication of Zaire Ebola virus and prevented a lethal outcome in 100% of the animals. Based on the studies, Favipiravir can be a candidate for the treatment of Ebola hemorrhagic fever. Favipiravir can be used for antiviral treatment of influenza A and B. Studies have shown that in addition to influenza virus, the drug also exhibits good antiviral activity against a variety of RNA viruses, such as Ebola virus, arena virus, Bunia virus, rabies virus and now COVID-19.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…